DK1187591T3 - IBD-associerede mikrobielle antigener og fremgangsmåder til at anvende samme - Google Patents
IBD-associerede mikrobielle antigener og fremgangsmåder til at anvende sammeInfo
- Publication number
- DK1187591T3 DK1187591T3 DK00930205.0T DK00930205T DK1187591T3 DK 1187591 T3 DK1187591 T3 DK 1187591T3 DK 00930205 T DK00930205 T DK 00930205T DK 1187591 T3 DK1187591 T3 DK 1187591T3
- Authority
- DK
- Denmark
- Prior art keywords
- ibd
- methods
- same
- microbial antigens
- associated microbial
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 230000000813 microbial effect Effects 0.000 title 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/303,120 US6309643B1 (en) | 1999-04-30 | 1999-04-30 | IBD-associated microbial antigens and methods of using same |
| PCT/US2000/011473 WO2000066067A2 (en) | 1999-04-30 | 2000-04-28 | Ibd-associated microbial antigens and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1187591T3 true DK1187591T3 (da) | 2010-06-28 |
Family
ID=23170632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00930205.0T DK1187591T3 (da) | 1999-04-30 | 2000-04-28 | IBD-associerede mikrobielle antigener og fremgangsmåder til at anvende samme |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US6309643B1 (enExample) |
| EP (1) | EP1187591B1 (enExample) |
| JP (2) | JP4666772B2 (enExample) |
| AT (1) | ATE461938T1 (enExample) |
| AU (1) | AU767861B2 (enExample) |
| CA (1) | CA2365898C (enExample) |
| DE (1) | DE60044058D1 (enExample) |
| DK (1) | DK1187591T3 (enExample) |
| ES (1) | ES2341752T3 (enExample) |
| HK (1) | HK1046287B (enExample) |
| NZ (1) | NZ514887A (enExample) |
| WO (1) | WO2000066067A2 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6309643B1 (en) | 1999-04-30 | 2001-10-30 | The Regents Of The University Of California | IBD-associated microbial antigens and methods of using same |
| US6821739B2 (en) * | 2000-10-13 | 2004-11-23 | The Regents Of The University Of California | Methods of diagnosing and treating Crohn's disease using Pseudomonas antigens |
| PT1458853E (pt) * | 2002-05-16 | 2010-02-23 | Absorber Ab | Processos de prova directa de compatibilidade específicos para dadores |
| US7662569B2 (en) * | 2003-04-11 | 2010-02-16 | Cedars-Sinai Medical Center | Methods of assessing Crohn's disease patient phenotype by I2 serologic response |
| US7759079B2 (en) * | 2004-05-13 | 2010-07-20 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
| US20060154276A1 (en) * | 2004-05-13 | 2006-07-13 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
| US11268149B2 (en) | 2004-12-08 | 2022-03-08 | Cedars-Sinai Medical Center | Diagnosis and treatment of inflammatory bowel disease |
| US12110555B2 (en) | 2004-12-08 | 2024-10-08 | Cedars-Sinai Medical Center | Diagnosis and treatment of inflammatory bowel disease |
| US7873479B2 (en) | 2005-12-01 | 2011-01-18 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
| WO2007124591A1 (en) * | 2006-05-03 | 2007-11-08 | University Of Manitoba | Microbial markers of inflammatory bowel disease |
| US7338135B1 (en) * | 2006-08-11 | 2008-03-04 | Hall David R | Holder for a degradation assembly |
| US8685741B1 (en) | 2007-03-07 | 2014-04-01 | Nestec S.A. | Methods for diagnosing irritable bowel syndrome |
| US20100129838A1 (en) * | 2008-11-11 | 2010-05-27 | Prometheus Laboratories Inc. | Methods for prediction of inflammatory bowel disease (ibd) using serologic markers |
| CA2758531C (en) * | 2009-04-14 | 2018-11-13 | Derren Barken | Inflammatory bowel disease prognostics |
| CA2766157A1 (en) | 2009-06-25 | 2010-12-29 | Hua Gong | Methods for diagnosing irritable bowel syndrome |
| WO2011060098A1 (en) | 2009-11-10 | 2011-05-19 | Prometheus Laboratories Inc. | Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis |
| ES2530175T3 (es) | 2011-02-17 | 2015-02-26 | Nestec S.A. | Ensayos para la detección de autoanticuerpos contra fármacos anti-TNF |
| WO2012154987A1 (en) | 2011-05-10 | 2012-11-15 | Nestec Sa | Methods of disease activity profiling for personalized therapy management |
| EP2710383B1 (en) | 2011-05-16 | 2017-01-11 | The University of Newcastle | Performance of a biomarker panel for irritable bowel syndrome |
| SG11201401536QA (en) | 2011-10-21 | 2014-05-29 | Nestec Sa | Methods for improving inflammatory bowel disease diagnosis |
| CN103175971B (zh) * | 2013-02-28 | 2016-10-05 | 苏州和锐医药科技有限公司 | 一种IgA抗体检测试剂盒 |
| EP3654037A1 (en) | 2013-12-03 | 2020-05-20 | Prometheus Biosciences, Inc. | Methods for predicting post-operative recurrence of crohn's disease |
| US10169541B2 (en) | 2014-10-21 | 2019-01-01 | uBiome, Inc. | Method and systems for characterizing skin related conditions |
| US9758839B2 (en) | 2014-10-21 | 2017-09-12 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features |
| US10793907B2 (en) | 2014-10-21 | 2020-10-06 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions |
| US10777320B2 (en) | 2014-10-21 | 2020-09-15 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions |
| US10381112B2 (en) | 2014-10-21 | 2019-08-13 | uBiome, Inc. | Method and system for characterizing allergy-related conditions associated with microorganisms |
| US10265009B2 (en) | 2014-10-21 | 2019-04-23 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features |
| US10409955B2 (en) | 2014-10-21 | 2019-09-10 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions |
| US10366793B2 (en) | 2014-10-21 | 2019-07-30 | uBiome, Inc. | Method and system for characterizing microorganism-related conditions |
| US10325685B2 (en) | 2014-10-21 | 2019-06-18 | uBiome, Inc. | Method and system for characterizing diet-related conditions |
| US11783914B2 (en) | 2014-10-21 | 2023-10-10 | Psomagen, Inc. | Method and system for panel characterizations |
| US10357157B2 (en) | 2014-10-21 | 2019-07-23 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features |
| US9754080B2 (en) | 2014-10-21 | 2017-09-05 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions |
| US10789334B2 (en) | 2014-10-21 | 2020-09-29 | Psomagen, Inc. | Method and system for microbial pharmacogenomics |
| US9760676B2 (en) | 2014-10-21 | 2017-09-12 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions |
| EP3209803A4 (en) | 2014-10-21 | 2018-06-13 | Ubiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics |
| US10073952B2 (en) | 2014-10-21 | 2018-09-11 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions |
| US10388407B2 (en) | 2014-10-21 | 2019-08-20 | uBiome, Inc. | Method and system for characterizing a headache-related condition |
| US10346592B2 (en) | 2014-10-21 | 2019-07-09 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues |
| US10410749B2 (en) | 2014-10-21 | 2019-09-10 | uBiome, Inc. | Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions |
| US9710606B2 (en) | 2014-10-21 | 2017-07-18 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues |
| US10395777B2 (en) | 2014-10-21 | 2019-08-27 | uBiome, Inc. | Method and system for characterizing microorganism-associated sleep-related conditions |
| US10311973B2 (en) | 2014-10-21 | 2019-06-04 | uBiome, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions |
| US10246753B2 (en) | 2015-04-13 | 2019-04-02 | uBiome, Inc. | Method and system for characterizing mouth-associated conditions |
| WO2017079653A2 (en) | 2015-11-06 | 2017-05-11 | Vetica Labs, Inc. | Methods of detecting inflammatory markers and treating inflammatory conditions in companion animals |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030124634A1 (en) * | 1996-04-30 | 2003-07-03 | University Of Guelph | Novel proteins involved in the synthesis and assembly of O-antigen in pseudomonas aeruginosa |
| US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| US6309643B1 (en) | 1999-04-30 | 2001-10-30 | The Regents Of The University Of California | IBD-associated microbial antigens and methods of using same |
-
1999
- 1999-04-30 US US09/303,120 patent/US6309643B1/en not_active Expired - Lifetime
-
2000
- 2000-04-28 WO PCT/US2000/011473 patent/WO2000066067A2/en not_active Ceased
- 2000-04-28 AU AU48065/00A patent/AU767861B2/en not_active Expired
- 2000-04-28 DK DK00930205.0T patent/DK1187591T3/da active
- 2000-04-28 EP EP00930205A patent/EP1187591B1/en not_active Expired - Lifetime
- 2000-04-28 NZ NZ514887A patent/NZ514887A/xx not_active IP Right Cessation
- 2000-04-28 DE DE60044058T patent/DE60044058D1/de not_active Expired - Lifetime
- 2000-04-28 JP JP2000614953A patent/JP4666772B2/ja not_active Expired - Lifetime
- 2000-04-28 CA CA2365898A patent/CA2365898C/en not_active Expired - Lifetime
- 2000-04-28 ES ES00930205T patent/ES2341752T3/es not_active Expired - Lifetime
- 2000-04-28 HK HK02106730.0A patent/HK1046287B/en not_active IP Right Cessation
- 2000-04-28 AT AT00930205T patent/ATE461938T1/de not_active IP Right Cessation
-
2001
- 2001-03-28 US US09/820,576 patent/US6320037B2/en not_active Expired - Lifetime
- 2001-09-27 US US09/966,608 patent/US6759530B2/en not_active Expired - Lifetime
-
2004
- 2004-04-30 US US10/835,914 patent/US7557194B2/en not_active Expired - Fee Related
-
2010
- 2010-07-27 JP JP2010168183A patent/JP2011019515A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ES2341752T3 (es) | 2010-06-28 |
| DE60044058D1 (de) | 2010-05-06 |
| US20010022971A1 (en) | 2001-09-20 |
| US6309643B1 (en) | 2001-10-30 |
| NZ514887A (en) | 2003-06-30 |
| AU767861B2 (en) | 2003-11-27 |
| AU4806500A (en) | 2000-11-17 |
| EP1187591B1 (en) | 2010-03-24 |
| CA2365898C (en) | 2012-03-13 |
| US20040197871A1 (en) | 2004-10-07 |
| ATE461938T1 (de) | 2010-04-15 |
| US20020115848A1 (en) | 2002-08-22 |
| US6759530B2 (en) | 2004-07-06 |
| EP1187591A2 (en) | 2002-03-20 |
| WO2000066067A3 (en) | 2001-02-15 |
| HK1046287B (en) | 2010-10-08 |
| JP2011019515A (ja) | 2011-02-03 |
| EP1187591A4 (en) | 2002-08-14 |
| US7557194B2 (en) | 2009-07-07 |
| HK1046287A1 (en) | 2003-01-03 |
| JP4666772B2 (ja) | 2011-04-06 |
| JP2002542798A (ja) | 2002-12-17 |
| US6320037B2 (en) | 2001-11-20 |
| WO2000066067A2 (en) | 2000-11-09 |
| CA2365898A1 (en) | 2000-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1187591T3 (da) | IBD-associerede mikrobielle antigener og fremgangsmåder til at anvende samme | |
| DK1093517T3 (da) | Neisseria-meningitidis-antigener og præparater | |
| DK1185691T3 (da) | Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf | |
| DK1212422T3 (da) | Humane CTLA-4-antistoffer og anvendelserne deraf | |
| MXPA02011656A (es) | Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos. | |
| DK1171417T3 (da) | Fremgangsmåde til fremstilling af 3-aryloxy-3-arylpropylaminer og mellemprodukter deraf | |
| CY1115634T1 (el) | Μεσα ανταγωνιστικης επιλεκτικης συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης | |
| DK1005540T3 (da) | IKK-beta-proteiner, nukleinsyrer og fremgangsmåder | |
| ATE291086T1 (de) | An entzündlichen darmerkrankungen beteiligte gene und deren verwendung | |
| DK1025236T3 (da) | Human checkpoint kinase, HCDS1, præparater og fremgangsmåde | |
| DK0845943T3 (da) | Nye peptider afledt fra humant heat shock protein 60 til behandling af diabetes, sammensætninger, fremgangsmåder og kits | |
| NO20011537L (no) | Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes | |
| ATE316577T1 (de) | Das goodpasture-antigen bindende protein | |
| BR9710919A (pt) | Proteina purificada sr-p70 | |
| DK1075523T3 (da) | Strukturelle proteiner hos fiskepankreassygdomsvirus og anvendelser deraf | |
| DK1406927T3 (da) | Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose | |
| ATE238347T1 (de) | Gen des familiären mittelmeerfiebers |